6.15
Clearance Models: Noncompartmental Models
Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. H…
Typically, clearance describes the drug elimination from the body using compartment models.
An alternative, the noncompartmental approach, estimates clearance mainly using experimental data collected after a single drug dose.
This approach uses rich sampling data and relates the volume of distribution to systemic exposure and administered dosage, allowing robust clearance computation without any assumptions.
Here, clearance depends on bioavailability, drug dose, and area under the concentration-time curve, or AUC.
Notably, AUC indicates total systemic exposure after a single dose. Using the trapezoidal rule, first calculate the observed AUC from time zero to t or the last detectable concentration. It is then extrapolated to infinity.
At the steady state, the amount of drug given equals the eliminated amount over that dosing interval, and the clearance equation becomes as follows.
During intravenous infusion's steady state, the clearance formula includes a constant dosing rate and the steady-state concentration, Css.
View the full transcript and gain access to JoVE Core videos
Q1: What is the main difference between noncompartmental and compartment models for clearance?
Noncompartmental models estimate clearance using experimental data from a single drug dose without requiring compartmental assumptions. Unlike compartment models, this approach relies on rich sampling data and relates volume of distribution to systemic exposure and dosage, enabling robust clearance computation directly from observed concentration-time curves.
Q2: How is the area under the concentration-time curve calculated in noncompartmental analysis?
The observed area under the concentration-time curve (AUC) is calculated from time zero to the last detectable concentration using the trapezoidal rule. This value is then extrapolated to infinity to estimate total systemic exposure after a single drug dose, providing a key parameter for clearance determination.
Q3: What factors does clearance depend on in noncompartmental models?
In noncompartmental models, clearance depends on three primary factors: bioavailability, the administered drug dose, and the area under the concentration-time curve (AUC). These parameters work together to characterize how efficiently the body eliminates a drug without requiring assumptions about compartmental structure.
Q4: How does the clearance equation change at steady state during intravenous infusion?
At steady state during intravenous infusion, the clearance formula incorporates a constant dosing rate and the steady-state concentration (Css). At this point, the amount of drug administered equals the amount eliminated over each dosing interval, creating a balance reflected in the modified clearance equation.
Q5: Why does the noncompartmental approach not require assumptions about drug distribution?
The noncompartmental approach uses rich, empirical sampling data collected directly after drug administration to calculate clearance. By relating observed volume of distribution to systemic exposure and dosage, it computes clearance robustly from actual experimental measurements rather than relying on theoretical compartmental models or distribution assumptions.
Q6: What does AUC represent in pharmacokinetic analysis?
The area under the concentration-time curve (AUC) represents the total systemic exposure to a drug following a single dose administration. It integrates drug concentration over time and serves as a fundamental parameter in noncompartmental clearance calculations, reflecting how much drug circulates in the body throughout the dosing interval.
Q7: How does the noncompartmental approach handle extrapolation of AUC data?
After calculating the observed AUC from time zero to the last detectable concentration using the trapezoidal rule, the noncompartmental approach extrapolates this value to infinity. This extrapolation accounts for drug elimination continuing beyond the final measurement point, ensuring complete estimation of systemic exposure for accurate clearance determination.